Novartis Ag · SIX:NOVN
Novartis — Q2 2023 Earnings Presentation
90 slides from Novartis's earnings presentation, Jul 18, 2023
Slide 1: Q2 2023 Results Investor Presentation
Company overview Financial review Conclusions Appendix References Q2 2023 Results Investor presentation 1 Investor Relations │ Q2 2023 Results
Slide 2: Disclaimer
Company overview Financial review Conclusions Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “wil
Slide 3: Company overview
Company Company overview overview Financial review Conclusions Appendix References Vas Narasimhan, M.D. Chief Executive Officer Company overview 3 NOVARTIS Q2 RESULTS | JULY 18, 2023 | NOVARTIS INVESTOR PRESENTATION 3 Investor Relations │ Q2 2023 Results
Slide 4: Novartis delivers strong sales growth, robust margin expansion and raises guidance
Company Company overview overview Financial review Conclusions Appendix References Q2 SUMMARY Novartis delivers strong sales growth, robust margin expansion and raises guidance Growth and Productivity Innovation and other milestones Q2, % cc Core margin Kisqali® 39.0% (+340 bps) NATALEE Ph3 at ASCO
Slide 5: Q2 growth driven by strong performance from Entresto, Kesimpta, Pluvicto and Kisqali
Company Company overview overview Financial review Conclusions Appendix References GROWTH Q2 growth driven by strong performance from Entresto®, Kesimpta®, Pluvicto® and Kisqali® Q2 sales Sales Growth vs. PY Growth vs. PY USD million USD million cc 1,516 391 37% 489 250 105% 240 230 nm Strong growth
Slide 6: Entresto delivering strong double-digit growth in all geographies
Company Company overview overview Financial review Conclusions Appendix References GROWTH Entresto® delivering strong double-digit growth in all geographies Sales evolution US weekly TRx1 Strong Q2 momentum USD m, % cc Total prescriptions (000) US: sales +38% cc, NBRx +17% vs PY, ~1.3m TRx in Q21 Ex
Slide 7: Cosentyx sales stabilized; expecting growth in H2
Company Company overview overview Financial review Conclusions Appendix References GROWTH Cosentyx® sales stabilized; expecting growth in H2 Sales evolution USD m, % cc Q2 performance Ex-US US US sales (-12% cc): Volume growth offset by revenue deductions (incl. PY base impact) Ex-US sales (+18% cc)
Slide 8: Kisqali continued strong momentum globally
Company Company overview overview Financial review Conclusions Appendix References GROWTH Kisqali® continued strong momentum globally, with increasing recognition of its differentiated profile Sales evolution US mBC NBRx share1 Consistent efficacy USD m, % cc Rolling 3 months, % Kisqali Ph3 OS resul
Slide 9: NATALEE results build on Kisqali's differentiated efficacy in mBC
Company Company overview overview Financial review Conclusions Appendix References INNOVATION NATALEE results1 build on Kisqali’s differentiated efficacy in mBC, support expansion into broad population2 of stage II, III eBC patients Ph3 NATALEE trial results1,2, presented at ASCO 2023 Robust efficac
Slide 10: Next steps for Kisqali
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Next steps for Kisqali® Continued NATALEE updated Expected filing in EU Pursuing broad label momentum in mBC, analysis for iDFS and and US Q3/Q4 2023 reflecting the ITT with increasing OS expected H2 popula
Slide 11: Kesimpta continues strong launch trajectory doubling sales vs. PY
Company Company overview overview Financial review Conclusions Appendix References GROWTH Kesimpta® continues strong launch trajectory doubling sales vs. PY Sales evolution US NBRx1 USD m, % cc Rolling 4 weeks Global sales 350 US: Growing faster than market1,2 Ex-US US TRx +80% YTD vs. PY (market fl
Slide 12: Pluvicto continued strong performance with improving supply
Company Company overview overview Financial review Conclusions Appendix References GROWTH Pluvicto® continued strong performance with improving supply Sales evolution Global sales, USD m Strong progress in Q2 240 Q2 sales of USD 240m, +14% USD vs. Q1 211 Millburn (US) and Zaragoza (EU) sites approve
Slide 13: Leqvio adoption expanding as we progress the launch
Company Company overview overview Financial review Conclusions Appendix References GROWTH Leqvio® adoption expanding as we progress the launch Leqvio® launch progressing steadily Building foundation for acceleration Global sales evolution US adoption USD m 2,600 facilities have ordered Leqvio (+18%
Slide 14: Scemblix strong sales growth driven by underlying demand
Company Company overview overview Financial review Conclusions Appendix References GROWTH Scemblix® strong sales growth driven by underlying demand and increasing recognition of efficacy and tolerability benefit Sales evolution USD m Q2 sales reflect strong demand from CML patients resistant or into
Slide 15: Key 2023 readouts for high-value medicines on track
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Key 2023 readouts for high-value medicines on track Key assets* with submission enabling readouts in 2023 Kisqali® Pluvicto® Iptacopan Ph3 NATALEE trial in PSMAfore trial in mCRPC PNH filed with FDA and EMA
Slide 16: Submission enabling readouts expected to increase in 2024-2025 timeframe
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Submission enabling readouts expected to increase in 2024-2025 timeframe Selected key assets* with submission enabling readouts in 2024-2025 Remibrutinib Pluvicto® Pelacarsen CSU mHSPC CVRR Primary analysis
Slide 17: Recent deals to bolster pipeline and strengthen technology platforms
Company Company overview overview Financial review Conclusions Appendix References STRATEGY Recent deals to bolster pipeline and strengthen technology platforms including late stage assets in IgAN, early stage asset in CNS Announced acquisitions (selected) Announced divestment Clinical stage: IgAN1
Slide 18: Financial review and 2023 guidance
Company overview Financial review Financial review Conclusions Appendix References Harry Kirsch Chief Financial Officer Financial review and 2023 guidance 18 NOVARTIS Q2 RESULTS | JULY 18, 2023 | NOVARTIS INVESTOR PRESENTATION 18 Investor Relations │ Q2 2023 Results
Slide 19: Very strong H1; Q2 continuing robust top and bottom-line growth
Company overview Financial review Financial review Conclusions Appendix References FINANCIAL PROFILE Very strong H1; Q2 continuing robust top and bottom-line growth... Group¹ Q2 Change vs. PY H1 Change vs. PY USD million 2023 % USD % cc 2023 % USD % cc Net Sales 13,622 7 9 26,575 5 8 Core Operating
Slide 20: Contributing to core margin improvements for Group
Company overview Financial review Financial review Conclusions Appendix References FINANCIAL PROFILE ... contributing to core margin improvements for Group Q2 2023 H1 2023 Core operating Core operating Net sales income Core Core margin Net sales income Core Core margin change vs. PY¹ change vs. PY¹
Slide 21: Consistent capital allocation priorities; initiating up-to USD 15bn share buyback
Company overview Financial review Financial review Conclusions Appendix References STRATEGY Novartis has maintained a consistent approach to its capital allocation priorities; initiating up-to USD 15bn share buyback Investing in the business Returning to shareholders USD 59bn distributed2 2018-2022
Slide 22: Raising 2023 guidance for Novartis excluding and including Sandoz
Company overview Financial review Financial review Conclusions Appendix References FINANCIAL PROFILE Raising 2023 guidance for Novartis excluding and including Sandoz Expected, barring unforeseen events; growth vs. PY in cc Previous guidance Innovative Medicines Sales expected to grow high single di
Slide 23: Maintaining Sandoz 2023 guidance
Company overview Financial review Financial review Conclusions Appendix References FINANCIAL PROFILE Maintaining Sandoz 2023 guidance Expected, barring unforeseen events; growth vs. PY in cc Sales expected to grow mid single digit 2023 Core OpInc expected to decline low double digit reflecting requi
Slide 24: Sandoz has returned to a position of strength
Company overview Financial review Financial review Conclusions Appendix References STRATEGY Sandoz has returned to a position of strength; expected spin-off will allow the business more flexibility to pursue its own growth strategy Strengthened Sandoz as a standalone... ... to execute on its six str
Slide 25: Sandoz delivered several consecutive quarters of growth
Company overview Financial review Financial review Conclusions Appendix References STRATEGY Sandoz delivered several consecutive quarters of growth, with a strong Q2 performance and ambitious mid-term outlook Mid-term guidance for standalone Sandoz Q2 performance1 Sales1 Sales growth rates1 in cc Mi
Slide 26: Novartis Board endorses 100% spin-off of Sandoz
Company overview Financial review Financial review Conclusions Appendix References STRATEGY Novartis Board endorses 100% spin-off of Sandoz, which will now go to shareholder vote at EGM in September Key milestones achieved Next steps CMDs held in Diverse and Novartis Board August 2023: EGM invitatio
Slide 27: Conclusions
Company overview Financial review Conclusions Conclusions Appendix References Vas Narasimhan, M.D. Chief Executive Officer 27 NOVARTIS Q2 RESULTS | JULY 18, 2023 | NOVARTIS INVESTOR PRESENTATION 27 Investor Relations │ Q2 2023 Results
Slide 28: Strong business momentum as we become a focused medicines company
Company overview Financial review Conclusions Conclusions Appendix References Strong business momentum as we become a focused medicines company Very strong H1 sales growth, robust margin expansion: Broad-based performance across core therapeutic areas and key geographies Confidence in near and mid-t
Slide 29: Appendix
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Appendix 29 Investor Relations │ Q2 2023 Results
Slide 30: 2023 expected key events; all selected H1 milestones achieved
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION 2023 expected key events; all selected H1 milestones achieved H1 2023 H2 2023 Status updat
Slide 31: Our pipeline projects at a glance
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Our pipeline projects at a glance Phase 1/2 Phase 3 Registration Total Innovative medicine
Slide 32: Novartis pipeline in Phase 1
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis pipeline in Phase 1 17 lead indications Lead indication Solid tumors Cardiovascul
Slide 33: Novartis pipeline in Phase 2
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis pipeline in Phase 2 25 lead indications Lead indication Solid Tumors Hematology C
Slide 34: Novartis pipeline in Phase 3
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis pipeline in Phase 3 6 lead indications Lead indication Solid Tumors Hematology Co
Slide 35: Novartis pipeline in registration
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis pipeline in registration 2 lead indications Lead indication Solid Tumors Hematolo
Slide 36: Novartis submission schedule: new molecular entities
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis submission schedule New Molecular Entities: Lead and supplementary indications Ca
Slide 37: Novartis submission schedule: existing brands
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis submission schedule Supplementary indications for existing brands Cardiovascular
Slide 38: H1 growth driven by strong performance from Entresto, Kesimpta, Pluvicto and Kisqali
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial Financial performance performance Innovation: Clinical trials Abbreviations GROWTH H1 growth driven by strong performance from Entresto®, Kesimpta®, Pluvicto® and Kisqali® H1 sales Sale
Slide 39: FY 2023 guidance on other financial KPIs
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial Financial performance performance Innovation: Clinical trials Abbreviations FINANCIAL PROFILE FY 2023 guidance on other financial KPIs Barring unforeseen events; (in cc) Group | Full ye
Slide 40: Expected currency impact for full year 2023
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial Financial performance performance Innovation: Clinical trials Abbreviations FINANCIAL PROFILE Expected currency impact for full year 2023 Currency impact vs. PY %pts, assuming mid-July
Slide 41: Net debt increased by USD 8.2bn
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial Financial performance performance Innovation: Clinical trials Abbreviations FINANCIAL PROFILE Net debt increased by USD 8.2bn mainly due to dividends and share buybacks, partly offset b
Slide 42: Clinical Trials Update
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Clinical Trials Update Includes selected ongoing
Slide 43: Cardiovascular
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Cardiovascular 43 Investor Relations │ Q2 2023 Re
Slide 44: iptacopan - CFB inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor iptacopan - CFB inhibit
Slide 45: iptacopan - CFB inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor iptacopan - CFB inhibit
Slide 46: Leqvio - siRNA (regulation of LDL-C)
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Leqvio® - siRNA (regulation of LDL-C) Leqvio® - s
Slide 47: Leqvio - siRNA (regulation of LDL-C)
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Leqvio® - siRNA (regulation of LDL-C) Leqvio® - s
Slide 48: Leqvio - siRNA (regulation of LDL-C)
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Leqvio® - siRNA (regulation of LDL-C) Leqvio® - s
Slide 49: pelacarsen - Antisense oligonucleotide targeting Lp(a)
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other pelacarsen - Antisense oligonucleotide (ASO) targ
Slide 50: XXB750 - NPR1 agonist
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other XXB750 - NPR1 agonist NCT05562934 (CXXB750B12201)
Slide 51: Immunology
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Immunology 51 Investor Relations │ Q2 2023 Result
Slide 52: Cosentyx - IL-17A inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Cosentyx® - IL-17A inhibitor Cosentyx® - IL-17A i
Slide 53: Cosentyx - IL-17A inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Cosentyx® - IL-17A inhibitor Cosentyx® - IL-17A i
Slide 54: ianalumab - BAFF-R inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF-R i
Slide 55: ianalumab - BAFF-R inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF-R i
Slide 56: ianalumab - BAFF-R inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF-R i
Slide 57: ligelizumab - IgE Inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ligelizumab - IgE Inhibitor NCT04984876 (CQGE031G
Slide 58: LNA043 - ANGPTL3 agonist
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other LNA043 - ANGPTL3 agonist NCT04864392 ONWARDS (CLN
Slide 59: remibrutinib - BTK inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other remibrutinib - BTK inhibitor remibrutinib - BTK i
Slide 60: Neuroscience
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Neuroscience 60 Investor Relations │ Q2 2023 Resu
Slide 61: Mayzent - S1P1,5 receptor modulator
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Mayzent® - S1P1,5 receptor modulator NCT04926818
Slide 62: MIJ821 - NR2B negative allosteric modulator
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other MIJ821 - NR2B negative allosteric modulator (NAM)
Slide 63: remibrutinib - BTK inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other remibrutinib - BTK inhibitor remibrutinib - BTK i
Slide 64: Zolgensma - SMN1 gene replacement therapy
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Zolgensma® - SMN1 gene replacement therapy Zolgen
Slide 65: Oncology
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Oncology 65 Investor Relations │ Q2 2023 Results
Slide 66: ianalumab - BAFF-R inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF-R i
Slide 67: ianalumab - BAFF-R inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor NCT05648968 VAYHIA (
Slide 68: iptacopan - CFB inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor NCT04889430 APPELHUS (C
Slide 69: Jakavi - JAK1/2 inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Jakavi® - JAK1/2 inhibitor Jakavi® - JAK1/2 inhib
Slide 70: JDQ443 - KRAS inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other JDQ443 - KRAS inhibitor NCT05132075 KontRASt-02 (
Slide 71: Kisqali - CDK4 inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Kisqali® - CDK4 inhibitor NCT03701334 NATALEE (CL
Slide 72: Piqray - PI3K-alpha inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Piqray® - PI3K-alpha inhibitor NCT04729387 EPIK-O
Slide 73: Pluvicto - Radioligand therapy target PSMA
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Pluvicto® - Radioligand therapy target PSMA Pluvi
Slide 74: Rydapt - Multi-targeted kinase inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Rydapt® - Multi-targeted kinase inhibitor NCT0359
Slide 75: sabatolimab - TIM3 antagonist
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other sabatolimab - TIM3 antagonist sabatolimab - TIM3
Slide 76: Scemblix - BCR-ABL inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Scemblix® - BCR-ABL inhibitor NCT04971226 ASC4FIR
Slide 77: TNO155 - SHP2 inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other TNO155 - SHP2 inhibitor NCT03114319 (CTNO155X2101
Slide 78: Other
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Health Biosimilars Other 78
Slide 79: Ophthalmology
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Ophthalmology Global Health Biosimi
Slide 80: Beovu - VEGF Inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Beovu® - VEGF Inhibitor NCT04278417 CONDOR (CRTH2
Slide 81: libvatrep - TRPV1 antagonist
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other libvatrep - TRPV1 antagonist NCT04630158 SAHARA (
Slide 82: Global Health
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Biosimi
Slide 83: Adakveo - P-selectin inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Biosimi
Slide 84: cipargamin - PfATP4 inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Biosimi
Slide 85: Coartem - PGH-1 (artemisinin combination therapy)
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Biosimi
Slide 86: ganaplacide - Non-artemisinin plasmodium falciparum inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Biosimi
Slide 87: Biosimilars
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Health Biosimilars Biosimila
Slide 88: aflibercept - VEGF inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Health Biosimilars afliberce
Slide 89: Abbreviations
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Abbreviations Abbreviations AI Auto-injector IgAN IgA nephropathy AIH Autoimmune hepatitis IPF Idiopathic pulmonary fibrosis aHUS a
Slide 90: References
Company overview Financial review Conclusions Appendix References References References Entresto® 1 IQVIA National Prescription Audit. 2 Approved indications differ by geography. Examples include “indicated to reduce the risk of cardiovascular death and hospitalization for HF in adult patients with